Active substance
Lansoprazole
- SFDA 15
- US FDA 37
- Health Canada 21
- US price lines 11
- NHS prices 4
- Safety 16
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| LANFAST 30MG CAPSULE | 30 mg | Capsule · Oral use | 15 Blister | SAR 58.10 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| LANSOMID 30 MG CAPSULE | 30 mg | Capsule · Oral use | 14 Blister | SAR 35.15 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| LONZET 15MG CAPSULES | 15 mg | Capsule, hard · Oral use | 14 Bottle | SAR 13.25 | Generic · OTC | Tabuk Pharmaceutical Manufacturing Company | Valid |
| LONZET 30MG CAPSULES | 30 mg | Capsule, hard · Oral use | 14 Bottle | SAR 26.50 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| PEPTAZOLE 15MG CAPSULE | 15 mg | Capsule · Oral use | 14 Blister | SAR 22.95 | Generic · OTC | SPIMACO ADDWAEIH | Valid |
| PEPTAZOLE 15MG CAPSULE | 15 mg | Capsule · Oral use | 28 Blister | SAR 45.90 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| PEPTAZOLE 30MG CAPSULE | 30 mg | Capsule · Oral use | 14 Blister | SAR 45.95 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| PEPTAZOLE 30MG CAPSULE | 30 mg | Capsule · Oral use | 28 Blister | SAR 91.90 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| TAKEPRON 15MG CAP. | 15 mg | Capsule, hard · Oral use | 14 Blister | SAR 22.95 | Generic · OTC | APM | Valid |
| TAKEPRON 30MG CAPS | 30 mg | Capsule, hard · Oral use | 14 Blister | SAR 45.95 | Generic · Prescription | APM | Valid |
| LANZOR 15MG CAPSULE | 15 mg | Capsule · Oral use | 30 Bottle | SAR 49.25 | Generic · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| LANZOR 15MG CAPSULE | 15 mg | Capsule · Oral use | 30 Bottle | SAR 93.00 | Generic · Prescription | SANOFI WINTHROP INDUSTRIE | Withdrawn by MAH · Not Marketed |
| LANZOR 30 MG CAPSUL | 30 mg | Capsule · Oral use | 15 Bottle | SAR 49.25 | Generic · Prescription | SANOFI WINTHROP INDUSTRIE | Withdrawn by MAH · Not Marketed |
| ULTRAZOLE | 15 mg | Capsule · Oral use | 14 Blister | SAR 29.50 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| ULTRAZOLE | 30 mg | Capsule · Oral use | 28 Blister | SAR 50.70 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ ASPIRATION PNEUMONIA PROPHYLAXIS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-EVIDENCE BASED FIRST LINE TREATMENT STRATEGY; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-SALVAGE THERAPIES; CORONARY ARTERY DISEASE; DENTAL ABSCESS-DENTAL PAIN; DYSPEPSIA; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; GASTROESOPHAGEAL REFLUX DISEASE (GERD); HIP AND KNEE REPLACEMENT SURGERY; LOW BACK PAIN; MIGRAINE/ HEADACHE; MYASTHENIA GRAVIS; NON-ST WAVE ELEVATED MYOCARDIAL INFARCTION (NSTEMI); PAIN MANAGEMENT IN CANCER PATIENTS; PEPTIC ULCER; POSTOPERATIVE PAIN; PSORIATIC ARTHRITIS; RHEUMATOID ARITHRITIS-SUPPORTIVE CARE AND ADRS MANAGEMENT; ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI); THROMBOTIC THROMBOCYTOPENIC PURPURA; TUBERCULOSIS-SUPPORTIVE CARE
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PREVACID | 30MG | capsule, delayed rel pellets · oral | TAKEDA PHARMS USA | Prescription | 10 May 1995 |
| PREVACID | 15MG; 30MG | tablet, orally disintegrating, delayed release · oral | TAKEDA PHARMS USA | Prescription | 30 Aug 2002 |
| PREVACID 24 HR | 15MG | capsule, delayed rel pellets · oral | PERRIGO PHARMA INTL | Over-the-counter | 18 May 2009 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | TEVA PHARMS | Prescription | 10 Nov 2009 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | MYLAN PHARMS INC | Prescription | 10 Nov 2009 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | DR REDDYS LABS LTD | Prescription | 15 Oct 2010 |
| LANSOPRAZOLE | 15MG | capsule, delayed rel pellets · oral | DR REDDYS LABS LTD | Over-the-counter | 18 May 2012 |
| LANSOPRAZOLE | 15MG | capsule, delayed rel pellets · oral | PERRIGO R AND D | Over-the-counter | 18 May 2012 |
| LANSOPRAZOLE | 15MG | capsule, delayed rel pellets · oral | GLENMARK PHARMS | Over-the-counter | 18 May 2012 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | APOTEX | Prescription | 14 Sep 2012 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | NATCO PHARMA LTD | Prescription | 18 Dec 2012 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | ZYDUS HLTHCARE | Prescription | 19 Aug 2013 |
| LANSOPRAZOLE | 15MG | capsule, delayed rel pellets · oral | NATCO | Over-the-counter | 13 Jan 2016 |
| LANSOPRAZOLE | 15MG | tablet, orally disintegrating, delayed release · oral | DEXCEL | Over-the-counter | 7 Jun 2016 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | XIROMED | Prescription | 25 Jul 2016 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | ADAPTIS | Prescription | 30 Aug 2017 |
| LANSOPRAZOLE | 15MG; 30MG | tablet, orally disintegrating, delayed release · oral | TEVA PHARMS USA | Prescription | 21 Sep 2017 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | CHARTWELL MOLECULAR | Prescription | 28 Sep 2017 |
| LANSOPRAZOLE | 15MG; 30MG | tablet, orally disintegrating, delayed release · oral | ZYDUS PHARMS | Prescription | 27 Nov 2018 |
| LANSOPRAZOLE | 15MG; 30MG | tablet, orally disintegrating, delayed release · oral | MYLAN | Prescription | 28 Nov 2018 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | ALKEM LABS LTD | Prescription | 18 Jan 2019 |
| LANSOPRAZOLE | 15MG; 30MG | capsule, delayed rel pellets · oral | HETERO LABS LTD III | Prescription | 18 May 2020 |
| LANSOPRAZOLE | 15MG; 30MG | tablet, orally disintegrating, delayed release · oral | DR REDDYS | Prescription | 1 Feb 2021 |
| LANSOPRAZOLE | 15MG; 30MG | tablet, orally disintegrating, delayed release · oral | AUROBINDO PHARMA LTD | Prescription | 28 Mar 2023 |
| PREVACID | 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule, delayed rel pellets · oral | TAKEDA PHARMS USA | Discontinued | 10 May 1995 |
12 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-LANSOPRAZOLE | 02293811 | 15 MG | CAPSULE (DELAYED-RELEASE) · ORAL | APOTEX INC |
| APO-LANSOPRAZOLE | 02293838 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | APOTEX INC |
| LANSOPRAZOLE | 02357682 | 15 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SANIS HEALTH INC |
| LANSOPRAZOLE | 02357690 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SANIS HEALTH INC |
| LANSOPRAZOLE | 02385767 | 15 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SIVEM PHARMACEUTICALS ULC |
| LANSOPRAZOLE | 02410389 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SIVEM PHARMACEUTICALS ULC |
| MYLAN-LANSOPRAZOLE | 02353830 | 15 MG | CAPSULE (DELAYED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-LANSOPRAZOLE | 02353849 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| NB-LANSOPRAZOLE | 02561239 | 15 MG | CAPSULE (DELAYED-RELEASE) · ORAL | NB PHARMA INC. |
| NB-LANSOPRAZOLE | 02561247 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | NB PHARMA INC. |
| PREVACID | 02165503 | 15 MG | CAPSULE (DELAYED-RELEASE) · ORAL | TAKEDA PHARMACEUTICALS AMERICA INC |
| PREVACID | 02165511 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | TAKEDA PHARMACEUTICALS AMERICA INC |
| PREVACID FASTAB | 02249464 | 15 MG | TABLET (DELAYED-RELEASE) · ORAL | TAKEDA PHARMACEUTICALS AMERICA INC |
| PREVACID FASTAB | 02249472 | 30 MG | TABLET (DELAYED-RELEASE) · ORAL | TAKEDA PHARMACEUTICALS AMERICA INC |
| PRO-LANSOPRAZOLE | 02366282 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | PRO DOC LIMITEE |
| SANDOZ LANSOPRAZOLE | 02385643 | 15 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ LANSOPRAZOLE | 02385651 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| TARO-LANSOPRAZOLE | 02402610 | 15 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| TARO-LANSOPRAZOLE | 02402629 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| TEVA-LANSOPRAZOLE | 02280515 | 15 MG | CAPSULE (DELAYED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| TEVA-LANSOPRAZOLE | 02280523 | 30 MG | CAPSULE (DELAYED-RELEASE) · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | GNP LANSOPRAZOLE DR 15 MG CAP | $0.40674 | per EA | 23 Sep 2026 |
| US NADAC | GS LANSOPRAZOLE DR 15 MG CAP | $0.40674 | per EA | 23 Sep 2026 |
| US NADAC | LANSOPRAZOLE DR 15 MG CAPSULE | $0.14737 | per EA | 23 Sep 2026 |
| US NADAC | LANSOPRAZOLE DR 15 MG CAPSULE | $0.40674 | per EA | 23 Sep 2026 |
| US NADAC | LANSOPRAZOLE DR 15 MG ODT | $1.92192 | per EA | 23 Sep 2026 |
| US NADAC | LANSOPRAZOLE DR 30 MG CAPSULE | $0.1061 | per EA | 23 Sep 2026 |
| US NADAC | LANSOPRAZOLE DR 30 MG ODT | $2.25583 | per EA | 23 Sep 2026 |
| US NADAC | PREVACID DR 15 MG SOLUTAB | $13.24954 | per EA | 23 Sep 2026 |
| US NADAC | PREVACID DR 30 MG CAPSULE | $13.2194 | per EA | 23 Sep 2026 |
| US NADAC | PREVACID DR 30 MG SOLUTAB | $13.21469 | per EA | 23 Sep 2026 |
| US NADAC | QC LANSOPRAZOLE DR 15 MG CAP | $0.40674 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Lansoprazole 15mg gastro-resistant capsules | £0.86 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Lansoprazole 15mg orodispersible tablets | £2.66 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lansoprazole 30mg gastro-resistant capsules | £1.15 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Lansoprazole 30mg orodispersible tablets | £5.10 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 1 Nov 2022 LANSOPRAZOLE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Jun 2022 PREVACID 24 HR — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 4 Mar 2022 PREVACID — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 4 Mar 2022 PREVACID — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 7 Jun 2018 PREVPAC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 9 Feb 2017 PRAC signal: Unexpected histopathological findings from a juvenile rat toxicity study
Action for MAH: update of the product information: No - EMA PRAC 12 Jan 2017 PRAC signal: Incident chronic kidney disease (CKD) and progression to end stage renal disease (ESRD)
Action for MAH: update of the product information: No - EMA PRAC 1 Dec 2016 PRAC signal: Gastric polyps
Action for MAH: update of the product information: Yes - EMA PRAC 29 Sep 2016 PRAC signal: Unexpected histopathological findings from a juvenile rat toxicity study
Action for MAH: update of the product information: No - EMA PRAC 2 Sep 2016 PRAC signal: Incident chronic kidney disease (CKD) and progression to end stage renal disease (ESRD)
Action for MAH: update of the product information: No - EMA PRAC 8 Jul 2016 PRAC signal: Elevated circulating levels of chromogranin A
Action for MAH: update of the product information: Yes - EMA PRAC 13 May 2016 PRAC signal: Unexpected histopathological findings from a juvenile rat toxicity study
Action for MAH: update of the product information: No - EMA PRAC 17 Mar 2016 PRAC signal: Elevated circulating levels of chromogranin A
Action for MAH: update of the product information: No - EMA PRAC 9 Jul 2015 PRAC signal: Subacute cutaneous lupus erythematosus (SCLE)
Action for MAH: update of the product information: Yes - EMA PRAC 13 Jun 2014 PRAC signal: Haemolytic anaemia
Action for MAH: update of the product information: No
Combinations containing Lansoprazole
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.